Donate For Public and Patients Store Search

F133 - Biologic Therapy in Dermatology Beyond Psoriasis

Monday, March 4; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Compare the different biologic treatments for atopic dermatitis, pruritus and hidradenitis suppurativa
  • Evaluate the efficacy of biologics in atopic dermatitis, pruritus and hidradenitis suppurativa
  • Select the best option for the treatment of atopic dermatitis, pruritus and hidradenitis suppurativa

Description

The session will begin with a thorough discussion with the use of biologics in atopic dermatitis. This will be followed by a lecture on the use of biologics in pruritus. The lecture to follow will overview biologics commonly used in Hidradenitis Suppurativa. The last lectures will summarize the authors' biologic experience in wound healing, hair loss and fillers reactions.

Disclosures

  • Dini, Valentina, MD, PhD: AbbVie – C(H); Eli Lilly and Company – C(H); KLOX TECHNOLOGIES – C(H); Mundipharma International – C(H); Novartis Pharmaceuticals Corp. – C(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Almirall – A(H), C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Asana Biosciences, LLC – A(H), C(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), C(H), I(Grants/Research Funding); Cara Therapeutics – A(H), C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Concert Pharmaceuticals – C(H), I(Grants/Research Funding); DBV Technologies – A(H), C(H); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), C(H), I(Grants/Research Funding); DS Biopharma – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding); EMD Serono – C(H); Escalier – A(H), C(H); FLX Bio – C(H); Galderma Research & Development, LLC – A(H), C(H), I(Grants/Research Funding); Glenmark Generics Inc. – A(H), C(H), I(Grants/Research Funding); Incyte Corporation – A(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – A(H), C(H), I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novan – A(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H), I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Sanofi – A(H), C(H); Sienna Biopharmaceuticals – A(H), C(H), I(Grants/Research Funding); UCB – I(Grants/Research Funding); Union Therapeutics – C(H), I(Grants/Research Funding);
  • Kerdel, Francisco, MD: AbbVie – SP(H); Amgen – SP(H); Astellas Pharma US, Inc – A(H); Celgene Corporation – I(H); Eisai Pharmaceuticals – SP(H); Eli Lilly and Company – SP(H); Janssen Biotech – I(H); Novartis – SP(H); Pfizer Inc. – SP(H); Regeneron – SP(H); Sanofi – SP(H); Stiefel a GSK company – I(H);
  • Miteva, Mariya, MD: Novartis – I(Grants/Research Funding);
  • Romanelli, Paolo, MD: no financial relationships exist with commercial interests.
  • Yosipovitch, Gil, MD: Galderma Laboratories, L.P. – A(H); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Menlo Therapeutics – A(H), I(Grants/Research Funding); Novartis – C(H); OPKO Health, Inc – C(H); Pfizer Inc. – A(H), I(Grants/Research Funding); Sanofi/Regeneron – A(H); Sienna Biopharmaceuticals – A(H); Sun Pharmaceutical Industries Ltd. – I(Grants/Research Funding); Trevi Therapeutics – A(H);
Event Details
  • Date
    Monday, March 4
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 146A
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Paolo Romanelli, MD, FAAD
Speakers
  • Emma Guttman, MD, PhD, FAAD - Handout
  • Francisco Kerdel, MD, FAAD
  • Gil Yosipovitch, MD
  • Mariya Miteva, MD
  • Valentina Dini, MD, PhD